Cello Therapeutics Limited

Cello Therapeutics, Inc. (Cello) is a leading biomedical company focused on developing novel nanoparticle delivery platforms for cancer treatment. Founded in 2016 in San Diego, CA, Cello develops biomimetic cell membrane-coated nanoparticles for cancer drug delivery, including chemotherapy agents, immunotherapy agents, or mRNA. Their cellular nanoparticles (CNPs) are comprised of three main components—drug payload, biocompatible polymer, and natural cellular membrane. The company aims to treat all types of cancers with a single delivery platform. On November 30, 2023, Cello Therapeutics, Inc. received IND clearance from the U.S. Food and Drug Administration (FDA) for its first immunotherapy nanoformulation CE120 to initiate first-in-human clinical trials for a variety of solid tumors.